Back toDiagnosis and Management of Drug-Induced Liver Injury (DILI): Clinical Trials and Post-Marketing
Diagnosis and Management of Drug-Induced Liver Injury (DILI): Clinical Trials and Post-Marketing
This new DIA training course is entirely dedicated to Drug-Induced Liver Injury (DILI). It is led by a Hepatologist with extensive experience in clinical assessment of DILI and who published ‘RUCAM’ the widely used causality assessment method of DILI. The course will cover the progress that has been made in the clinical detection and prevention of DILI in clinical trials and in post marketing phase. Regulatory guidelines need to be understood for an optimal assessment of DILI cases. Better use of typical tools will be emphasised in order to improve patient safety and drug monitoring in new drug development, especially in large populations. This course will provide tools, explanations, examples and several exercises for a better understanding of DILI and how best to apply that knowledge in day-to-day work.